Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies
Findings indicate that population-level immunity to clade 2.3.4.4b H5 viruses is dominated by NA-directed antibodies, with important implications for pandemic risk assessment.
MF59-adjuvanted A/Astrakhan influenza vaccine induces cross-neutralizing H5N1 antibodies in ferrets against circulating clade 2.3.4.4b viruses
Findings suggest broad protection induced by the CSL Seqirus pandemic vaccine against contemporary clade 2.3.4.4b A(H5N1) viruses.
Small molecule–constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins
Authors report on the applicability of a CLIPS (chemical linkage of peptides onto scaffolds) chemistry–based strategy to miniaturize an anti-influenza hemagglutinin (HA) antibody into design of stable and functional bicyclic peptides.
Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K
The rapid expansion of H3N2 subclade K represents a major public health concern. This study reports antibody responses to H3N2 subclade K and other influenza strains before and after influenza vaccination.
Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019.
Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus
Immune responses against neuraminidase (NA) and hemagglutinin (HA) are critical for developing effective influenza vaccines, yet their role in influenza transmission remains unclear.
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.
Clesrovimab for Prevention of RSV Disease in Healthy Infants
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein.
